Literature DB >> 23710710

Heterogeneity of neuroblastoma cell lines in insulin-like growth factor 1 receptor/Akt pathway-mediated cell proliferative responses.

Lei Qi1, Hidemi Toyoda, Vipin Shankar, Naoto Sakurai, Keishirou Amano, Kentaro Kihira, Tadashi Iwasa, Takao Deguchi, Hiroki Hori, Eiichi Azuma, Esteban C Gabazza, Yoshihiro Komada.   

Abstract

Insulin-like growth factor 1 receptor (IGF-1R) is critical for cancer cell proliferation; however, recent clinical anti-IGF-1R trials did not show clear clinical benefit in cancer therapy. We hypothesized that IGF-1R signaling-mediated proliferative response is heterogeneous in neuroblastoma (NB) cells, and analyzed the cell growth of 31 NB cell lines cultured in three different media, including Hybridoma-SFM medium (with insulin) and RPMI1640 with/without 10% FBS. Three growth patterns were found. In response to IGF and insulin, cell proliferation and Akt phosphorylation were upregulated in 13 cell lines, and suppressed by MK2206 (Akt inhibitor) and picropodophyllin (IGF-1R inhibitor). Interestingly, 3 of these 13 cell lines showed Akt self-phosphorylation and cell proliferation in RPMI1640; their proliferation was downregulated by anti-IGF-1 or anti-IGF-2 neutralizing antibody, suggesting the existence of an autocrine loop in the IGF-1R/Akt pathway. Eighteen NB cell lines did not proliferate in RPMI1640, even though Akt phosphorylation was upregulated by IGF and insulin. Based on the heterogeneous response of the IGF-1R/Akt pathway, the 31 NB cell lines could be classified into group 1 (autocrine IGF-mediated), group 2 (exogenous IGF-mediated) and group 3 (partially exogenous IGF-mediated) NB cell lines. In addition, group 3 NB cell lines were different from group 1 and 2, in terms of serum starvation-induced caspase 3 cleavage and picropodophyllin-induced G2/M arrest. These results indicate that the response of the IGF-1R/Akt pathway is an important determinant of the sensitivity to IGF-1R antagonists in NB. To our knowledge, this is the first report describing heterogeneity in the IGF-1R/Akt-mediated proliferation of NB cells.
© 2013 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23710710     DOI: 10.1111/cas.12204

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  8 in total

1.  A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma.

Authors:  Qi Zhao; Hoa Tran; Dimiter S Dimitrov; Nai-Kong V Cheung
Journal:  Int J Cancer       Date:  2015-05-19       Impact factor: 7.396

2.  BET and CDK Inhibition Reveal Differences in the Proliferation Control of Sympathetic Ganglion Neuroblasts and Adrenal Chromaffin Cells.

Authors:  Jessica Sriha; Caroline Louis-Brennetot; Cécile Pierre-Eugène; Sylvain Baulande; Virginie Raynal; Amira Kramdi; Igor Adameyko; Uwe Ernsberger; Thomas Deller; Olivier Delattre; Isabelle Janoueix-Lerosey; Hermann Rohrer
Journal:  Cancers (Basel)       Date:  2022-06-01       Impact factor: 6.575

Review 3.  Impacts of Oxidative Stress and PI3K/AKT/mTOR on Metabolism and the Future Direction of Investigating Fucoidan-Modulated Metabolism.

Authors:  Jun-Ping Shiau; Ya-Ting Chuang; Yuan-Bin Cheng; Jen-Yang Tang; Ming-Feng Hou; Ching-Yu Yen; Hsueh-Wei Chang
Journal:  Antioxidants (Basel)       Date:  2022-05-06

4.  Mesenchymal stromal cell secretome up-regulates 47 kDa CXCR4 expression, and induce invasiveness in neuroblastoma cell lines.

Authors:  Vipin Shankar; Hiroki Hori; Kentaro Kihira; Qi Lei; Hidemi Toyoda; Shotaro Iwamoto; Yoshihiro Komada
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

5.  Response of neuroblastoma cells to RF currents as a function of the signal frequency.

Authors:  María Luisa Hernández-Bule; Enrique Medel; Clara Colastra; Raquel Roldán; Alejandro Úbeda
Journal:  BMC Cancer       Date:  2019-09-05       Impact factor: 4.430

Review 6.  Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.

Authors:  Roberto Ciaccio; Piergiuseppe De Rosa; Sara Aloisi; Marta Viggiano; Leonardo Cimadom; Suleman Khan Zadran; Giovanni Perini; Giorgio Milazzo
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

7.  Nafamostat mesylate prevents metastasis and dissemination of neuroblastoma through vascular endothelial growth factor inhibition.

Authors:  Mari Morimoto; Hidemi Toyoda; Kaori Niwa; Ryo Hanaki; Taro Okuda; Daisuke Nakato; Keishiro Amano; Shotaro Iwamoto; Masahiro Hirayama
Journal:  Mol Clin Oncol       Date:  2022-07-21

Review 8.  Type I insulin-like growth factor receptor signaling in hematological malignancies.

Authors:  Deeksha Vishwamitra; Suraj Konnath George; Ping Shi; Ahmed O Kaseb; Hesham M Amin
Journal:  Oncotarget       Date:  2017-01-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.